The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia
- 31 May 2000
- journal article
- Published by Elsevier BV in Experimental Hematology
- Vol. 28 (5), 551-557
- https://doi.org/10.1016/s0301-472x(00)00142-9
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon- in Chronic Myeloid Leukemia PatientsBlood, 1999
- The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damageNature, 1999
- Interaction of c-Abl and p73α and their collaboration to induce apoptosisNature, 1999
- p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damageNature, 1999
- Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.JCI Insight, 1998
- Effects of interferon-alpha (IFN-α) administration on leucocytes in healthy humansClinical and Experimental Immunology, 1997
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- The nuclear tyrosine kinase c-abl negatively regulates cell growthCell, 1994
- Tyrphostin induced growth inhibitionAnti-Cancer Drugs, 1994
- Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1986